Outcomes with Single Tremelimumab Regular Interval Durvalumab (STRIDE) for Unresectable Hepatocellular Carcinoma in the US Veterans Administration

Authors

• Shalini Bansal, Thomas Jefferson UniversityFollow
• Priya Amin
• Courtney Williamson
• Stephen Valerio
• David Kaplan

Document Type

Article

Publication Date

3-26-2026

Comments

This article is the author’s final published version in Cancers, Volume 18, Issue 7, 2026, Article number 1085.

The published version is available at https://doi.org/10.3390/cancers18071085. Copyright © 2026 by the authors.

Abstract

Background: HIMALAYA demonstrated that STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) compared with sorafenib in participants with unresectable hepatocellular carcinoma (HCC). This retrospective, real-world cohort study evaluated outcomes with STRIDE in veterans with HCC. Methods: Patients diagnosed with HCC between 1 January 2008 and 28 February 2024 who received ≥1 dose of STRIDE for unresectable disease were included. Data were collected from the Veteran Affairs Corporate Data Warehouse. Safety and efficacy were evaluated overall and for subgroups of patients with Child–Pugh A versus Child–Pugh B cirrhosis, viral versus non-viral HCC, and those with versus without prior non-systemic therapies. Results: Overall, 107 patients (100.0% male) were included. Median (interquartile range) age was 72.2 (68.0–76.1) years. There were 22 Grade 3–4 adverse events reported (three in patients with Child–Pugh B cirrhosis). Median OS (95% CI) was 12.4 (9.1–22.1) months and 5.2 (1.5–9.3) months in patients with Child–Pugh A (n = 81; 75.7%) and Child–Pugh B cirrhosis (n = 26; 24.3%), respectively. In patients with viral (n = 64; 59.8%) versus non-viral etiology (n = 43; 40.2%), median OS (95% CI) was 10.5 (7.0–25.6) months versus 9.0 (4.6–16.0) months, respectively. In patients without (n = 30; 28.0%) versus with prior non-systemic therapies (n = 77; 72.0%), median OS (95% CI) was 7.7 (2.8–17.3) months versus 11.1 (7.6–17.6) months, respectively. Conclusions: These results suggest that STRIDE is well tolerated and may offer a survival benefit to a broad range of patients with unresectable HCC, representing populations that are more reflective of real-world clinical practice.

Recommended Citation

Bansal, Shalini; Amin, Priya; Williamson, Courtney; Valerio, Stephen; and Kaplan, David, "Outcomes with Single Tremelimumab Regular Interval Durvalumab (STRIDE) for Unresectable Hepatocellular Carcinoma in the US Veterans Administration" (2026). Student Papers, Posters & Projects. Paper 200.
https://jdc.jefferson.edu/student_papers/200

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

Language

English